SS-31 Peptide Benefits: What the Elamipretide Research Actually Shows

The honest summary of the table: a specific, well-characterised mechanism, a large and mostly negative randomised programme in rare and serious diseases, one positive open-label story in Barth syndrome, and nothing at all in the people who most often ask about it.

SS-31 is a tetrapeptide, four amino acids in an alternating aromatic and cationic pattern, developed by Hazel Szeto and Peter Schiller. Its development code was MTP-131 and its generic drug name is elamipretide; all three names are the same molecule. The pattern lets it cross cell membranes and concentrate on the inner mitochondrial membrane without a transporter, where it binds a single lipid, cardiolipin, that holds the membrane's folds (the cristae) in shape and organises the respiratory complexes that make ATP. A 2014 review in the British Journal of Pharmacology calls it a cardiolipin-protective compound. It is not a hormone, not a growth hormone secretagogue, and not a general antioxidant. Every benefit below hangs off that cardiolipin story.

What the research describes. The foundational finding, in the Journal of the American Society of Nephrology in 2013, used a fluorescent analogue of the peptide to show high-affinity binding to cardiolipin. In rat kidneys subjected to ischaemia (loss of blood flow), pre-treatment protected the cristae from collapsing and prevented mitochondrial swelling.

The reactive oxygen angle. When cytochrome c, which normally carries electrons along the respiratory chain, binds oxidised cardiolipin, it starts acting as a peroxidase and damages the membrane it sits on. The same work reports that the SS-31 and cardiolipin complex inhibits that peroxidase activity while leaving the electron-carrying role intact. This is the specific sense in which SS-31 is said to "reduce reactive oxygen species": preventing one source at one site, rather than mopping up afterwards.

Evidence type. Animal and cell.

Strength. The best-characterised part of the SS-31 story, and more specific than most peptides can claim. It is a mechanism, not a benefit anyone has measured in a healthy person.

What the research describes. With the cristae protected, the 2013 animal work reports much faster recovery of ATP once blood flow returned. The 2014 review extends this to a broader idea: that a cardiolipin-protective compound could restore cellular energy production across conditions that share energy failure.

Evidence type. Animal.

What it means. That broader idea is the theoretical basis for every use of SS-31 outside the trials. Whether it holds in a given human population is exactly what the trials below tested, and in most of them it did not show up on the main endpoint.

What the research describes. Barth syndrome is a rare genetic disorder in which cardiolipin is not remodelled into its mature form. TAZPOWER, in Genetics in Medicine in 2021, was a randomised, double-blind, placebo-controlled crossover in twelve males aged 12 to 35: 40 mg daily or placebo for 12 weeks each. Neither primary endpoint, the six-minute walk test and a symptom score, was met in the randomised part.

The open-label extension. Ten participants continued on 40 mg daily. At 36 weeks the paper reports a 95.9 metre gain in walk distance, a symptom improvement, and improvements in knee extensor strength and some cardiac measures. The 168-week results, in 2024, report the walk gain sustained, fatigue scores below baseline at every visit, improved heart volumes, and the diagnostic cardiolipin ratio improving on treatment. Eight of ten reached the final visit.

Evidence type. Human, randomised (negative) then open-label (positive).

Strength. The strongest human benefit for SS-31, and the basis for the FDA's September 2025 accelerated approval of the branded drug, which rested on knee extensor strength as an intermediate endpoint. A confirmatory trial is a condition of that approval. Open-label results in ten people with a rare disease are not evidence for anyone without it, and a compounded vial is not a substitute for specialist care in Barth syndrome.

What the research describes. The largest programme. A five-day intravenous study in Neurology in 2018 (36 adults) reported a dose-dependent walk-distance signal that fell just short of significance. MMPOWER-2, in the Journal of Cachexia, Sarcopenia and Muscle in 2020, a 30-person crossover of 40 mg daily for four weeks, found a walk difference that did not reach significance and a patient-reported fatigue improvement that did.

The phase 3 result. MMPOWER-3, in Neurology in 2023, randomised 218 people to 40 mg daily or placebo for 24 weeks. It did not meet either primary endpoint: the walk and fatigue differences were close to zero. The authors classify it as Class I evidence that elamipretide does not improve walking distance or fatigue at 24 weeks in this population. A 2024 post hoc analysis in the Orphanet Journal of Rare Diseases found one genetic subgroup trended toward benefit, which is hypothesis-generating by definition.

Evidence type. Human, randomised.

What it means. This is the clearest test of the "more energy, less fatigue" idea in people with mitochondrial disease, at the full trial dose, and on its main endpoints it was negative. That matters for every fatigue claim made about SS-31.

What the research describes. PROGRESS-HF, in the Journal of Cardiac Failure in 2020, randomised 71 people with reduced-ejection-fraction heart failure to placebo, 4 mg or 40 mg daily for 28 days. The primary endpoint, a heart volume measured on cardiac MRI, was not different from placebo at either dose, nor was ejection fraction. Adverse event rates were similar across groups.

Evidence type. Human, randomised.

Strength. Negative. SS-31 is not a heart failure treatment.

What the research describes. ReCLAIM-2, in Ophthalmology Science in 2024, randomised 176 people with dry age-related macular degeneration 2:1 to 40 mg daily or placebo for 48 weeks. It did not meet its primary endpoints, which measured vision in low light and the area of retinal atrophy. On a pre-specified secondary measure, treatment was associated with a 43 per cent reduction in progression of a specific kind of photoreceptor-layer loss, and more people gained ten or more letters of low-light acuity (14.6 against 2.1 per cent).

Evidence type. Human, randomised; positive on secondary endpoints only.

What it means. A secondary endpoint is a reason for a further trial, not a demonstrated benefit. SS-31 is not a treatment for macular degeneration.

What the research describes. Nothing directly. No study has measured energy or fatigue in healthy adults given SS-31. The claim is an extrapolation from the mechanism and from the disease trials, where the fatigue result was positive in one short crossover and negative in the phase 3.

What prescribers report. Some people describe steadier energy through the day or less tiredness after exertion over the first months; many notice nothing, which is normal. These are patterns described by prescribers, not trial endpoints, and subjective energy is the outcome most open to expectation.

Evidence type. None direct.

What it means. Tiredness most often has an ordinary cause: iron, thyroid, B12, sleep, mood, medication. Peptides for energy and fatigue sets out what a physician looks at first and where SS-31 sits alongside NAD+ and MOTS-c.

What the research describes. No human study. There are no randomised human trials of elamipretide in healthy adults, in age-related fatigue, in athletic performance or in any longevity indication. The ageing claim comes from the idea that mitochondrial function declines with age and the mechanism might counter that.

Evidence type. None direct in people.

Strength. An inference, not a finding. Peptides for longevity and anti-aging puts SS-31 alongside the other compounds discussed for ageing and the evidence each has.

• A benefit in people without a mitochondrial disease. Every randomised trial enrolled people with a diagnosed disease.
• That the compounded dose does what the trial dose did. The trials used 40 mg daily; Pepti's typical directions deliver 0.5 mg, one eightieth of that.
• An effect on walking or fatigue in the largest population studied. MMPOWER-3 is a clean negative on those endpoints.
• An effect size or timeline for any use outside the trials.
• Long-term safety in healthy adults.

Prices are all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Some prescribers combine these, since they work through different described mechanisms; no trial has tested any combination. The MOTS-c evidence is set out in MOTS-c benefits.

The trials report elamipretide as well tolerated across hundreds of people for up to a year, at 40 mg daily. There is no formal interaction list, which is why the intake asks for every medication you take, and kidney impairment is worth raising because the approved label reduces the dose in severe cases. SS-31 is not used in pregnancy or breastfeeding. Elamipretide is not named on the 2026 WADA Prohibited List; a tested athlete should still confirm with their anti-doping organisation first.

SS-31 (Elamipretide) is a 5 mL multi-dose vial at 2 mg/mL (10 mg per vial), $249 a month all-in. The typical directions are 0.25 mL (25 units) subcutaneously Monday through Friday mornings, 20 doses, about four weeks; the full conversion is in SS-31 dosage. Pepti is cash-pay and does not bill insurance. Vials ship ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads, and refills run every 28 days, one vial per fill. Your physician sets your directions after reviewing your intake, and they are printed on the vial.

The compounded vial is not the FDA-approved elamipretide product, which is approved only for Barth syndrome. Since September 2025 elamipretide has been a component of an approved drug, which makes it eligible for 503A compounding subject to the FDA's "essentially a copy" rule; it has never been on the FDA's Category 2 list.

SS-31 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes SS-31 in every state except Oklahoma, plus DC The step-by-step page is how to get SS-31 prescribed online.